Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K5UF
|
|||
| Former ID |
DIB019609
|
|||
| Drug Name |
PMID24432909C8e
|
|||
| Synonyms |
4cd0; GTPL8137; ZINC98050687; BDBM50448785; NCGC00485046-01; P-355; AWJ
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C22H23FN6O3S
|
|||
| Canonical SMILES |
CC1=C(SC(=N1)C(C)(CO)O)C2=CC(=C(N=C2)N)OC(C)C3=C(C=CC(=C3)F)N4N=CC=N4
|
|||
| InChI |
1S/C22H23FN6O3S/c1-12-19(33-21(28-12)22(3,31)11-30)14-8-18(20(24)25-10-14)32-13(2)16-9-15(23)4-5-17(16)29-26-6-7-27-29/h4-10,13,30-31H,11H2,1-3H3,(H2,24,25)/t13-,22-/m1/s1
|
|||
| InChIKey |
DIXMBHMNEHPFCX-MCMMXHMISA-N
|
|||
| CAS Number |
CAS 1549629-82-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ALK tyrosine kinase receptor (ALK) | Target Info | Inhibitor | [1] |
| BDNF/NT-3 growth factors receptor (TrkB) | Target Info | Inhibitor | [1] | |
| Leukocyte receptor tyrosine kinase (LTK) | Target Info | Inhibitor | [1] | |
| Proto-oncogene c-Fer (FER) | Target Info | Inhibitor | [1] | |
| Proto-oncogene c-Fes (FES) | Target Info | Inhibitor | [1] | |
| Proto-oncogene c-Ros (ROS1) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Non-small cell lung cancer | |||
| MAPK signaling pathway | ||||
| Neurotrophin signaling pathway | ||||
| Alcoholism | ||||
| Pathway Interaction Database | SHP2 signaling | |||
| Posttranslational regulation of adherens junction stability and dissassembly | ||||
| Neurotrophic factor-mediated Trk receptor signaling | ||||
| Reactome | NGF-independant TRKA activation | |||
| WikiPathways | Differentiation Pathway | |||
| SIDS Susceptibility Pathways | ||||
| BDNF signaling pathway | ||||
| Spinal Cord Injury | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.